Intuitive Surgical, Inc. (BKK:ISRG01)
Thailand · Delayed Price · Currency is THB | Market Cap | 4.79T -21.4% |
| Revenue (ttm) | 345.36B +21.4% |
| Net Income | 97.23B +20.3% |
| EPS | 268.56 +20.5% |
| Shares Out | n/a |
| PE Ratio | 49.29 |
| Forward PE | 37.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 276,386 |
| Open | 3.080 |
| Previous Close | 3.100 |
| Day's Range | 3.040 - 3.080 |
| 52-Week Range | 2.880 - 4.120 |
| Beta | 1.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 16, 2026 |
About Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling,... [Read more]
Financial Performance
In 2025, Intuitive Surgical's revenue was $10.06 billion, an increase of 20.51% compared to the previous year's $8.35 billion. Earnings were $2.86 billion, an increase of 22.97%.
Financial numbers in USD Financial StatementsNews
BMO starts Intuitive Surgical initiated with an Outperform on durable earnings
As previously reported, BMO Capital analyst Vik Chopra initiated coverage of Intuitive Surgical (ISRG) with an Outperform rating and $518 price target The da Vinci 5 upgrade cycle is still…
Intuitive Surgical initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Intuitive Surgical (ISRG) with an Outperform rating and $518 price target
Citi adds ‘upside 90-day catalyst watch’ on Intuitive Surgical
Citi is adding an “upside 90-day catalyst watch” on Intuitive Surgical (ISRG) while keeping a Buy rating and $590 price target on shares. Shares have been pressured year-to-date by concerns…
Intuitive Surgical price target lowered to $430 from $480 at Evercore ISI
Evercore ISI lowered the firm’s price target on Intuitive Surgical (ISRG) to $430 from $480 and keeps an In Line rating on the shares. The firm’s Q2 preview for MedTech,…
Robotics Then & Now: 2000 to 2026 by the Numbers
In 2000, a “robot” mostly meant a caged arm bolted to a car line, repeating one welded seam. Most could not see, none could leave their cells unsupervised, and a full installation ran into six figures...
Intuitive Surgical price target lowered to $515 from $520 at BofA
BofA analyst Travis Steed lowered the firm’s price target on Intuitive Surgical (ISRG) to $515 from $520 and keeps a Buy rating on the shares. Noting that the firm’s services…
Intuitive Surgical price target lowered to $366 from $440 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Intuitive Surgical (ISRG) to $366 from $440 and keeps a Sell rating on the shares.
Intuitive Surgical names Taylor Patton chief commercial and marketing officer
Intuitive Surgical (ISRG) announced the promotion of Taylor Patton to chief commercial and marketing officer, effective July 1. Patton, formerly global senior VP of the company’s endoluminal business,...
Intuitive Announces New Chief Commercial and Marketing Officer Taylor Patton
Current Chief Commercial and Marketing Officer Henry Charlton to become SVP of Global Business Operations Current Chief Commercial and Marketing Officer Henry Charlton to become SVP of Global Business...
Intuitive Surgical price target lowered to $558 from $621 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Intuitive Surgical (ISRG) to $558 from $621 and keeps a Buy rating on the shares. MedTech has experienced one of its weakest…
Intuitive Announces Innovations to Advance Quintuple Aim
Latest innovations include enhanced telecollaboration capabilities, extended uses for Force Feedback technology, and advancements in product and instrument reliability and security Latest innovations ...
Intuitive Surgical price target lowered to $520 from $650 at BofA
BofA lowered the firm’s price target on Intuitive Surgical (ISRG) to $520 from $650 and keeps a Buy rating on the shares. After having hosted 34 medtech companies last week…
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) a...
Intuitive Surgical removes 8mm SureForm 30 gray reloads, FDA reports
The FDA is aware that Intuitive Surgical (ISRG) has issued a letter to affected customers recommending all 8mm SureForm 30 gray reloads for curved-tip staplers be removed from where they…
Intuitive Surgical Transcript: AGM 2026
The meeting saw all board nominees elected and all proposals approved, including executive compensation and auditor ratification. Strong financial results were reported for 2025 and Q1 2026, with continued focus on global expansion, innovation, and manufacturing optimization amid competitive and geopolitical challenges.
Intuitive Surgical (ISRG) Beats Q1 Expectations. The Bull Case Builds
Intuitive Surgical ($ISRG) remains an attractive long-term story following another strong quarter. The Q1 results released on April 21 reinforced the durability of its growth model. The leader in mini...
The Biggest Takeaway From ISRG Earnings
The key takeaway from Intuitive Surgical's (ISRG) Q1 2026 results is the implementation of a fundamental “Platform Refresh Wall.” In addition to the $2.50 EPS exceeding expectations and a revenue grow...
Intuitive Surgical price target lowered to $651 from $712 at Barclays
Barclays lowered the firm’s price target on Intuitive Surgical (ISRG) to $651 from $712 and keeps an Overweight rating on the shares post the Q1 report. The company reported a…
Intuitive Surgical beats quarterly expectations on surgical robot demand
Intuitive Surgical on Tuesday beat Wall Street estimates for first-quarter profit and revenue, as the firm rode the wave of robust demand for its minimally invasive surgical robots used in complex m...
Intuitive Announces First Quarter Earnings
SUNNYVALE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today...
Intuitive Surgical Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong 17% procedure growth and 23% revenue growth, led by robust adoption of da Vinci 5, Ion, and SP platforms, with notable expansion in the U.S. and Europe. Guidance for full-year procedure growth and gross margin was raised, while ongoing challenges persist in China and Japan.
Intuitive Surgical Earnings release: Q1 2026
Intuitive Surgical released its Q1 2026 earnings on April 21, 2026, summarizing the period's financial results.
Intuitive Surgical Quarterly report: Q1 2026
Intuitive Surgical has published its Q1 2026 quarterly earnings report on April 21, 2026.
Intuitive Surgical Slides: Q1 2026
Intuitive Surgical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.
SurGenTec Secures FDA 510(k) Clearance for TiLink™ SI joint fusion- Now Navigation Compatible
BOCA RATON, Fla.--(BUSINESS WIRE)---- $ISRG #FDAcleared--SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has ...